Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial -

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Information type: Other primary research
Source: Lancet Public Health
Specialities: Cancers | Renal and urologic disorders
Summary
In this single arm phase 2 trial (n=310) atezolizumab improved the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) by 15% (95%CI= 11-20) compared to a historical overall response rate of 10%.
UKMi comment
Increased levels of programmed death ligand 1 (PD-L1) expression on immune cells were associated with increased response. A related commentary discusses the implications of this trial in detail and implications for future research.
Related links: Related Commentary